Cargando…

Integrating thousands of PTEN variant activity and abundance measurements reveals variant subgroups and new dominant negatives in cancers

BACKGROUND: PTEN is a multi-functional tumor suppressor protein regulating cell growth, immune signaling, neuronal function, and genome stability. Experimental characterization can help guide the clinical interpretation of the thousands of germline or somatic PTEN variants observed in patients. Two...

Descripción completa

Detalles Bibliográficos
Autores principales: Matreyek, Kenneth A., Stephany, Jason J., Ahler, Ethan, Fowler, Douglas M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518224/
https://www.ncbi.nlm.nih.gov/pubmed/34649609
http://dx.doi.org/10.1186/s13073-021-00984-x
_version_ 1784584177325178880
author Matreyek, Kenneth A.
Stephany, Jason J.
Ahler, Ethan
Fowler, Douglas M.
author_facet Matreyek, Kenneth A.
Stephany, Jason J.
Ahler, Ethan
Fowler, Douglas M.
author_sort Matreyek, Kenneth A.
collection PubMed
description BACKGROUND: PTEN is a multi-functional tumor suppressor protein regulating cell growth, immune signaling, neuronal function, and genome stability. Experimental characterization can help guide the clinical interpretation of the thousands of germline or somatic PTEN variants observed in patients. Two large-scale mutational datasets, one for PTEN variant intracellular abundance encompassing 4112 missense variants and one for lipid phosphatase activity encompassing 7244 variants, were recently published. The combined information from these datasets can reveal variant-specific phenotypes that may underlie various clinical presentations, but this has not been comprehensively examined, particularly for somatic PTEN variants observed in cancers. METHODS: Here, we add to these efforts by measuring the intracellular abundance of 764 new PTEN variants and refining abundance measurements for 3351 previously studied variants. We use this expanded and refined PTEN abundance dataset to explore the mutational patterns governing PTEN intracellular abundance, and then incorporate the phosphatase activity data to subdivide PTEN variants into four functionally distinct groups. RESULTS: This analysis revealed a set of highly abundant but lipid phosphatase defective variants that could act in a dominant-negative fashion to suppress PTEN activity. Two of these variants were, indeed, capable of dysregulating Akt signaling in cells harboring a WT PTEN allele. Both variants were observed in multiple breast or uterine tumors, demonstrating the disease relevance of these high abundance, inactive variants. CONCLUSIONS: We show that multidimensional, large-scale variant functional data, when paired with public cancer genomics datasets and follow-up assays, can improve understanding of uncharacterized cancer-associated variants, and provide better insights into how they contribute to oncogenesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13073-021-00984-x.
format Online
Article
Text
id pubmed-8518224
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85182242021-10-20 Integrating thousands of PTEN variant activity and abundance measurements reveals variant subgroups and new dominant negatives in cancers Matreyek, Kenneth A. Stephany, Jason J. Ahler, Ethan Fowler, Douglas M. Genome Med Research BACKGROUND: PTEN is a multi-functional tumor suppressor protein regulating cell growth, immune signaling, neuronal function, and genome stability. Experimental characterization can help guide the clinical interpretation of the thousands of germline or somatic PTEN variants observed in patients. Two large-scale mutational datasets, one for PTEN variant intracellular abundance encompassing 4112 missense variants and one for lipid phosphatase activity encompassing 7244 variants, were recently published. The combined information from these datasets can reveal variant-specific phenotypes that may underlie various clinical presentations, but this has not been comprehensively examined, particularly for somatic PTEN variants observed in cancers. METHODS: Here, we add to these efforts by measuring the intracellular abundance of 764 new PTEN variants and refining abundance measurements for 3351 previously studied variants. We use this expanded and refined PTEN abundance dataset to explore the mutational patterns governing PTEN intracellular abundance, and then incorporate the phosphatase activity data to subdivide PTEN variants into four functionally distinct groups. RESULTS: This analysis revealed a set of highly abundant but lipid phosphatase defective variants that could act in a dominant-negative fashion to suppress PTEN activity. Two of these variants were, indeed, capable of dysregulating Akt signaling in cells harboring a WT PTEN allele. Both variants were observed in multiple breast or uterine tumors, demonstrating the disease relevance of these high abundance, inactive variants. CONCLUSIONS: We show that multidimensional, large-scale variant functional data, when paired with public cancer genomics datasets and follow-up assays, can improve understanding of uncharacterized cancer-associated variants, and provide better insights into how they contribute to oncogenesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13073-021-00984-x. BioMed Central 2021-10-14 /pmc/articles/PMC8518224/ /pubmed/34649609 http://dx.doi.org/10.1186/s13073-021-00984-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Matreyek, Kenneth A.
Stephany, Jason J.
Ahler, Ethan
Fowler, Douglas M.
Integrating thousands of PTEN variant activity and abundance measurements reveals variant subgroups and new dominant negatives in cancers
title Integrating thousands of PTEN variant activity and abundance measurements reveals variant subgroups and new dominant negatives in cancers
title_full Integrating thousands of PTEN variant activity and abundance measurements reveals variant subgroups and new dominant negatives in cancers
title_fullStr Integrating thousands of PTEN variant activity and abundance measurements reveals variant subgroups and new dominant negatives in cancers
title_full_unstemmed Integrating thousands of PTEN variant activity and abundance measurements reveals variant subgroups and new dominant negatives in cancers
title_short Integrating thousands of PTEN variant activity and abundance measurements reveals variant subgroups and new dominant negatives in cancers
title_sort integrating thousands of pten variant activity and abundance measurements reveals variant subgroups and new dominant negatives in cancers
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518224/
https://www.ncbi.nlm.nih.gov/pubmed/34649609
http://dx.doi.org/10.1186/s13073-021-00984-x
work_keys_str_mv AT matreyekkennetha integratingthousandsofptenvariantactivityandabundancemeasurementsrevealsvariantsubgroupsandnewdominantnegativesincancers
AT stephanyjasonj integratingthousandsofptenvariantactivityandabundancemeasurementsrevealsvariantsubgroupsandnewdominantnegativesincancers
AT ahlerethan integratingthousandsofptenvariantactivityandabundancemeasurementsrevealsvariantsubgroupsandnewdominantnegativesincancers
AT fowlerdouglasm integratingthousandsofptenvariantactivityandabundancemeasurementsrevealsvariantsubgroupsandnewdominantnegativesincancers